1. Scrip

Biogen Prepares More Doubtful Phase III Results For FDA Scrutiny, This Time In ALS

Will Hope To Ride On Coattails Of Amylyx’s Thumbs Up

 
• By Andrew McConaghie

After the Aduhelm controversy, Biogen has another neurodegenerative disease drug which so far can only show efficacy against surrogate biomarkers – will the FDA be swayed again this time?

Biogen
Even if approved, tofirsen looks unlikely to be a big earner for Biogen, which is depending on other late-stage candidates to revive its fortunes.

Biogen is preparing to talk to the US Food and Drug Administration about its amyotrophic lateral sclerosis (ALS) candidate tofersen, and is hopeful of approval, even though the drug failed its pivotal study.

The company first announced disappointing topline data from its Phase III VALOR study evaluating tofersen for the treatment of a...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D

Lilly’s Muscle Builder Looks Strong In GLP-1 Obesity Combo

 
• By Andrew McConaghie

Bimagrumab added to Wegovy increased weight loss and preserved muscle mass, but analysts want to see more safety and efficacy results from a combination with Zepbound.

Mineralys Eyes NDA As Lorundrostat Scores CKD Win In Race With AstraZeneca

 
• By Sushmita Panda

As it races AstraZeneca’s baxdrostat to market, Mineralys plans to file an NDA later this year, backed by strong efficacy and safety data across four trials.

Chinese Developers Showcase Potentially Differentiated Weight Loss Assets At ADA

 
• By Xu Hu

Multiple Chinese firms presented at this year’s ADA meeting, with a focus on weight reduction efficacy for mostly early clinical stage assets. While limited information was given on lean mass preservation, several companies are progressing drugs and combos to address this need.